Loading data for ENGNW — first visit, this takes a few seconds.

enGene Therapeutics Inc. (ENGNW)

NasdaqCM: ENGNW · リアルタイム株価 · USD

0.27

+0.04 (17.39%)

終値時点： Aug 31, 2026, 1:30 PM

アラート

Alert

株価、主要な数字、最新ニュースをひとまとめにしたページです。

データがありません

買気配	0
時価総額	n/a
売上高（TTM）	n/a
純利益（TTM）	-127M
	-0.28
	n/a
	n/a
	n/a
PBR（TTM）	0.07
PSR（TTM）	0.00
決算発表日	n/a

売気配	0
出来高	550
平均出来高（20日）	n/a
始値	2.10
前日終値	0.23
当日レンジ	0.27 - 0.27
52週レンジ	0.27 - 0.27
アナリスト	n/a
目標株価	n/a
配当	n/a
権利落ち日	n/a

ENGNWについて

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings In...

[続きを読む]

業種

セクター

IPO日 Jul 17, 2026

従業員数 81

上場取引所 NasdaqCM

ティッカー ENGNW

ウェブサイト https://www.engene.com

企業情報の全文

業績

2025年のenGene Therapeuticsの売上高は0で、前年の0からundefined%の増加でした。利益は-117.3Mで、112.73%の増加でした。

財務諸表

決算サプライズ

enGene TherapeuticsはInvalid Dateに四半期決算を発表しました：

売上高は n/a で、予想を下回りました $0, うち NaN% の前年比増加にあたります.
EPSはで、予想を下回りました , うち NaN% の前年比増加にあたります.

株価が動いた理由

ニュース

3週間前 · MarketBeat

enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market

enGene (NASDAQ:ENGN) outlined its view of the high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer, or NMIBC, market, citing market research that it believes supports a l...

2か月前 · BioPharma Dive

Neumora depression drug fails; EnGene to cut 50% of staff

Neumora’s stumble is the latest setback for a once-promising class of brain drugs. Elsewhere, a cell therapy manufacturing specialist took steps toward an IPO and J&J made its latest U.S investment.

5か月前 · MarketBeat

enGene Shares Detalimogene NMIBC Trial Changes, FDA Endpoint Shift, and 2027 Approval Path at Conference

Executives from enGene (NASDAQ:ENGN) provided an update on the company’s detalimogene program in non-muscle invasive bladder cancer (NMIBC), discussing recent protocol changes, regulatory interactions...

5か月前 · MarketBeat

enGene Highlights 2026 Data Catalysts, BLA Plans for Bladder Cancer Gene Therapy at Barclays Conference

enGene (NASDAQ:ENGN) CEO Ron Cooper said the company’s focus is advancing its DDX platform, a proprietary non-viral gene therapy technology, with its lead program detalimogene being developed for non-...

5か月前 · MarketBeat

enGene CEO Pitches Detalimogene as Community-Friendly NMIBC Option, Teases Q2 LEGEND Data Update

enGene (NASDAQ:ENGN) Chief Executive Officer Ron Cooper used a presentation at the Citizens Life Sciences Conference to outline the company’s approach to non-muscle invasive bladder cancer (NMIBC), em...

2ページ中1ページ

enGene Therapeutics Inc. (ENGNW)